What development phase is CEFSULODIN in?

CEFSULODIN is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CEFSULODIN

FDA-approved active Small molecule Quality 15/100

At a glance

Generic name	CEFSULODIN
Drug class	cefsulodin
Target	Beta-adrenergic receptor kinase 1, Lethal(3)malignant brain tumor-like protein 1, Protein-tyrosine phosphatase 1C
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CEFSULODIN CI brief — competitive landscape report
CEFSULODIN updates RSS · CI watch RSS